Monday, May 17, 2021 5/17/2021

Enzyme Replacement Therapeutics for Rare Childhood Genetic Diseases: An ERT Delivery System that Mitigates Immune-sensitization

Award Number: R44HD087099
ORGANIZATION: NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By Issue Date FY or Funding FY:

View Award Abstract

The long-range goal of this research is to develop an enzyme replacement therapy (ERT) technology for genetic metabolic diseases that is effective in mitigating the problem of immune sensitization that has hindered previous ERT technologies. ERT drugs have been approved for treating almost a dozen lysosomal diseases (LDs), however, the induction of patient anti-ERT antibodies has emerged as a significant limitation for some of these drugs reducing their effectiveness. Because early/infantile-onset forms of LDs comprise the most severe mutations, the development of immune sensitization is more prevalent in younger patients. These children often show dramatic life-saving improvements upon treatment onset, however, progress may stop and quickly decline if these patients develop neutralizing antibodies to the ERT drug. Most current ERTs for LDs exploit the Mannose-6-Phospate (M6P) receptor for uptake into disease cells and the predominant class of anti-ERT antibodies interfere with this uptake process. However, the technology developed by BioStrategies LC uses an alternative plant RTB lectin-based mechanism for ERT cell uptake. Using the Hurler MPS I model we have shown in both MPS I lysosomal disease cell cultures and subsequent short-term in vivo mouse Phase I SBIR studies of IDUA:RTB that active enzyme is successfully delivered by RTB in the presence of neutralizing antibodies against mammalian cell derived IDUA (mcd-IDUA). Based on these promising preliminary results, our goal in this SBIR Phase II follow-on project is to demonstrate bio-distribution and long-term therapeutic effectiveness of RTB delivered ERT in Hurler mice at the high level of rigor that would support FDA approval to begin IND clinical trials. Specific aims of this Phase II project are to: 1) Assess short-term biodistribution and pharmacodynamics comparing our IDUA:RTB drug to the mcd-IDUA drug in immune-sensitized Hurler mice, and 2) Evaluate effects of anti-drug antibodies following long-term administration of the IDUA-RTB verses mcd-IDUA drugs. Success in these experiments would lay the foundation for further preclinical research leading to a successful IND application to FDA to initiate clinical trials in immune compromised Hurler patients. Our broader long-term goal is to develop this new ERT delivery system for treating immune-sensitized patients for other lysosomal and metabolic diseases.


Issue Date FY	Funding FY	Recipient Name	DUNS Number	City	State	CFDA Number	CFDA Program Title	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2021 ( Subtotal = $905,262 )
2021	2021	BIOSTRATEGIES LC	621026140	STATE UNIVERSITY	AR	93.865	Child Health and Human Development Extramural Research	000	3	3/26/2021	NON-COMPETING CONTINUATION	$905,262


Issue Date FY: 2020 ( Subtotal = $1,144,737 )
2020	2020	BIOSTRATEGIES LC	621026140	STATE UNIVERSITY	AR	93.865	Child Health and Human Development Extramural Research	000	2	4/8/2020	COMPETING CONTINUATION	$1,144,737


Grand Total All Awards = $2,049,999

Sum of Action Amount is $2,049,999;

Grand Total = $2,049,999

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Enzyme Replacement Therapeutics for Rare Childhood Genetic Diseases: An ERT Delivery System that Mitigates Immune-sensitization

Award Number: R44HD087099

ORGANIZATION: NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer